Anaplastic Lymphoma Kinase Variants and the Percentage of ALK-Positive Tumor Cells and the Efficacy of Crizotinib in Advanced NSCLC

Clinical Lung Cancer

Volumn 17, Issue 3, 2016, Pages 223-231

  Lei, Yuan Yuan ^a   Yang, Jin Ji ^a   Zhang, Xu Chao ^a   Zhong, Wen Zhao ^a   Zhou, Qing ^a   Tu, Hai Yan ^a   Tian, Hong Xia ^a   Guo, Wei Bang ^a   Yang, Lu Lu ^a   Yan, Hong Hong ^a   Chen, Hua Jun ^a   Xie, Zhi ^a   Su, Jian ^a   Han, Jie Fei ^a   Wu, Yi Long ^a  

^a GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL   (China)

Author keywords

Anaplastic lymphoma kinase variants; Crizotinib; Non small cell lung cancer; Percentage of ALK positive cells; Progression free survival

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; CRIZOTINIB; MICROTUBULE ASSOCIATED PROTEIN 4; ANTINEOPLASTIC AGENT; PHARMACOLOGICAL BIOMARKER; PROTEIN TYROSINE KINASE; PYRAZOLE DERIVATIVE; PYRIDINE DERIVATIVE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER PATIENT; CLINICAL EVALUATION; CORRELATIONAL STUDY; DRUG EFFICACY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE REARRANGEMENT; GENETIC VARIABILITY; HUMAN; MAJOR CLINICAL STUDY; MALE; NON SMALL CELL LUNG CANCER; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; TREATMENT RESPONSE; CANCER STAGING; CARCINOMA, NON-SMALL-CELL LUNG; FOLLOW UP; GENETIC POLYMORPHISM; GENETICS; LUNG NEOPLASMS; MIDDLE AGED; MORTALITY; SURVIVAL ANALYSIS; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BIOMARKERS, PHARMACOLOGICAL; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; POLYMORPHISM, GENETIC; PYRAZOLES; PYRIDINES; RECEPTOR PROTEIN-TYROSINE KINASES; SURVIVAL ANALYSIS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84951061478     PISSN: 15257304     EISSN: 19380690     Source Type: Journal    
DOI: 10.1016/j.cllc.2015.09.002     Document Type: Article

References (33)

1. T. Li, H.J. Kung, P.C. Mack, and et al. Genotyping and genomic profiling of non-small-cell lung cancer: implications for current and future therapies J Clin Oncol 31 2013 1039 1049
2. R. Buettner, J. Wolf, and R.K. Thomas Lessons learned from lung cancer genomics: the emerging concept of individualized diagnostics and treatment J Clin Oncol 31 2013 1858 1865
3. E.L. Kwak, Y.J. Bang, D.R. Camidge, and et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer N Engl J Med 363 2010 1693 1703
4. D.R. Camidge, Y.J. Bang, E.L. Kwak, and et al. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study Lancet Oncol 13 2012 1011 1019
5. Kim DW, Ahn MJ, Shi YK, et al. Results of a global phase II study with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC) (abstract 7533). J Clin Oncol 2012; 30(suppl).
6. A.T. Shaw, D.W. Kim, K. Nakagawa, and et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer N Engl J Med 368 2013 2385 2394
7. B.J. Solomon, T. Mok, D.W. Kim, and et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer N Engl J Med 371 2014 2167 2177
8. S.H. Ou, C.H. Bartlett, M. Mino-Kenudson, and et al. Crizotinib for the treatment of ALK-rearranged non-small-cell lung cancer: a success story to usher in the second decade of molecular targeted therapy in oncology Oncologist 17 2012 1351 1375
9. Y.L. Wu, and L.Y. Gou Prevalence of driver mutations in non-small-cell lung cancers in the People's Republic of China Lung Cancer Targets Ther 5 2014 1 9
10. K. Takeuchi, Y.L. Choi, Y. Togashi, and et al. KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer Clin Cancer Res 15 2009 3143 3149
11. K. Rikova, A. Guo, Q. Zeng, and et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer Cell 131 2007 1190 1203
12. Y. Togashi, M. Soda, S. Sakata, and et al. KLC1-ALK: a novel fusion in lung cancer identified using a formalin-fixed paraffin-embedded tissue only PLoS One 7 2012 e31323
13. S.H. Ou, S.J. Klempner, J.R. Greenbowe, and et al. Identification of a novel HIP1-ALK fusion variant in non-small-cell lung cancer (NSCLC) and discovery of ALK I1171 (I1171N/S) mutations in two ALK-rearranged NSCLC patients with resistance to Alectinib J Thorac Oncol 9 2014 1821 1825
14. M. Hong, R.N. Kim, J.Y. Song, and et al. HIP1-ALK, a novel fusion protein identified in lung adenocarcinoma J Thorac Oncol 9 2014 419 422
15. D.D. Fang, B. Zhang, Q. Gu, and et al. HIP1-ALK, a novel ALK fusion variant that responds to crizotinib J Thorac Oncol 9 2014 285 294
16. Y.L. Choi, M.E. Lira, M. Hong, and et al. A novel fusion of TPR and ALK in lung adenocarcinoma J Thorac Oncol 9 2014 563 566
17. A. Drilon, L. Wang, M.E. Arcila, and et al. Broad, hybrid capture-based next-generation sequencing identifies actionable genomic alterations in lung adenocarcinomas otherwise negative for such alterations by other genomic testing approaches Clin Cancer Res 21 2015 3631 3639
18. L. Shan, P. Jiang, F. Xu, and et al. BIRC6-ALK, a Novel fusion gene in ALK break-apart FISH-negative lung adenocarcinoma, responds to crizotinib J Thorac Oncol 10 2015 e37 e39
19. C.K. Lee, Y.L. Wu, P.N. Ding, and et al. Impact of specific epidermal growth factor receptor (EGFR) mutations and clinical characteristics on outcomes after treatment with EGFR tyrosine kinase inhibitors versus chemotherapy in EGFR-mutant lung cancer: a meta-analysis J Clin Oncol 33 2015 1958 1965
20. J.C. Yang, Y.L. Wu, M. Schuler, and et al. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials Lancet Oncol 16 2015 141 151
21. D.R. Camidge, S.A. Kono, A. Flacco, and et al. Optimizing the detection of lung cancer patients harboring anaplastic lymphoma kinase (ALK) gene rearrangements potentially suitable for ALK inhibitor treatment Clin Cancer Res 16 2010 5581 5590
22. Q. Zhou, X.C. Zhang, Z.H. Chen, and et al. Relative abundance of EGFR mutations predicts benefit from gefitinib treatment for advanced non-small-cell lung cancer J Clin Oncol 29 2011 3316 3321
23. M.B. Beasley, E. Brambilla, and W.D. Travis The 2004 World Health Organization classification of lung tumors Semin Roentgenol 40 2005 90 97
24. X. Zhang, S. Zhang, X. Yang, and et al. Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression Mol Cancer 9 2010 188
25. P. Therasse, S.G. Arbuck, E.A. Eisenhauer, and et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 2000 205 216
26. E.A. Eisenhauer, P. Therasse, J. Bogaerts, and et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) Eur J Cancer 45 2009 228 247
27. J.M. Heuckmann, H. Balke-Want, F. Malchers, and et al. Differential protein stability and ALK inhibitor sensitivity of EML4-ALK fusion variants Clin Cancer Res 18 2012 4682 4690
28. A.T. Shaw, S.H. Ou, Y.J. Bang, and et al. Crizotinib in ROS1-rearranged non-small-cell lung cancer N Engl J Med 371 2014 1963 1971
29. D.R. Camidge, M. Theodoro, D.A. Maxson, and et al. Correlations between the percentage of tumor cells showing an anaplastic lymphoma kinase (ALK) gene rearrangement, ALK signal copy number, and response to crizotinib therapy in ALK fluorescence in situ hybridization-positive nonsmall cell lung cancer Cancer 118 2012 4486 4494
30. J.F. Gainor, D.S. Tan, T. De Pas, and et al. Progression-free and overall survival in ALK-positive NSCLC patients treated with sequential crizotinib and ceritinib Clin Cancer Res 21 2015 2745 2752
31. J.K. Won, B. Keam, J. Koh, and et al. Concomitant ALK translocation and EGFR mutation in lung cancer: a comparison of direct sequencing and sensitive assays and the impact on responsiveness to tyrosine kinase inhibitor Ann Oncol 26 2015 348 354
32. J.J. Yang, X.C. Zhang, J. Su, and et al. Lung cancers with concomitant EGFR mutations and ALK rearrangements: diverse responses to EGFR-TKI and crizotinib in relation to diverse receptors phosphorylation Clin Cancer Res 20 2014 1383 1392
33. X. Zhang, S. Lu, L. Zhang, and et al. The Chinese expert consensus opinion of the diagnosis of ALK-positive NSCLC (2013 version) [in Chinese] Chin J Pathol 42 2013 402 406